FOLH1 and prostate cancer: The mode of action of [177Lu]Lu-PSMA-617 begins with specific binding of the compound to the prostate-specific membrane antigen (PSMA) [3], a transmembrane protein that is overexpressed in prostate cancer with expression levels rising with higher progression [4, 5].